EZ1 Stock Overview
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Enzon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.12 |
| 52 Week High | US$0.29 |
| 52 Week Low | US$0.062 |
| Beta | 0.35 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -39.59% |
| 3 Year Change | -79.83% |
| 5 Year Change | -40.50% |
| Change since IPO | -99.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| EZ1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -2.0% |
| 1Y | -39.6% | -21.1% | -0.3% |
Return vs Industry: EZ1 underperformed the German Biotechs industry which returned -20.5% over the past year.
Return vs Market: EZ1 underperformed the German Market which returned -1.9% over the past year.
Price Volatility
| EZ1 volatility | |
|---|---|
| EZ1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EZ1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EZ1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | n/a | Rick Feinstein | enzon.com |
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug.
Enzon Pharmaceuticals, Inc. Fundamentals Summary
| EZ1 fundamental statistics | |
|---|---|
| Market cap | €6.22m |
| Earnings (TTM) | -€224.54k |
| Revenue (TTM) | €24.22k |
256.9x
P/S Ratio-27.7x
P/E RatioIs EZ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EZ1 income statement (TTM) | |
|---|---|
| Revenue | US$26.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$26.00k |
| Other Expenses | US$267.00k |
| Earnings | -US$241.00k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0032 |
| Gross Margin | 100.00% |
| Net Profit Margin | -926.92% |
| Debt/Equity Ratio | 0% |
How did EZ1 perform over the long term?
See historical performance and comparison